Monotherapy With Immune Checkpoint Inhibitors in Patients With Recurrent and/or Metastatic Sinonasal Squamous Cell Carcinoma
Immunotherapy may represent a treatment option for patients with SNSCC. Given the limited sample size, these results should be interpreted with caution. Our findings highlight the urgent need to include SNSCC patients in future prospective trials to clarify the role of immunotherapy in this underrepresented population.
Authors
- Thorsten Fuereder (ORCID: https://orcid.org/0000-0001-5356-6452)
- Rajiv Bhalla (ORCID: https://orcid.org/0000-0003-1421-3667)
- Alexander Lein (ORCID: https://orcid.org/0000-0002-9912-9837)
- Faris F. Brkic (ORCID: https://orcid.org/0000-0002-0770-6677)
- Gregor Heiduschka (ORCID: https://orcid.org/0000-0003-1862-5992)
- Manuel Stöth (ORCID: https://orcid.org/0000-0002-8069-4342)
- Lorenz Kadletz‐Wanke
- Lukas Kenner (ORCID: https://orcid.org/0000-0003-2184-1338)
- Stephan Hackenberg (ORCID: https://orcid.org/0000-0001-6995-1849)
- Agmal Scherzad (ORCID: https://orcid.org/0000-0003-3396-5995)
- Julia Schnoell (ORCID: https://orcid.org/0000-0001-9772-4395)
- Archana Jaiswal
Institutions
- University of Veterinary Medicine Vienna (AT)
- Salford Royal NHS Foundation Trust (GB)
- Vienna General Hospital (AT)
- Manchester University NHS Foundation Trust (GB)
- Christian Doppler Laboratory for Thermoelectricity (AT)
- Universitätsklinikum Würzburg (DE)
- Center For Biomarker Research In Medicine (AT)
- Medical University of Vienna (AT)
- Umeå University (SE)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2025-11-27
- DOI
- https://doi.org/10.1002/cam4.71391
- Citations
- 2
- Primary Topic
- Head and Neck Surgical Oncology
- Type
- article
- Field-Weighted Citation Impact
- 4.01